Research & Development of 3 novel Lateral Flow Assays

Chromacare aims to revolutionize precision health through Mobile-based At-home Lab Tests. To the end, over the next 12 months, commencing in early 2024, Chromacare will develop up to three novel quantitative Lateral Flow Assays (LFA) that will be measured with our proprietary Chromacare App.
We will employ two Chemistry PhD graduates on a full-time basis to perform the necessary research and validation work required for the development of the LFAs. The two PhD graduates we have identified are uniquely suited to excel in this role.
On the diagnostic front, Chromacares goal is a prime example of predictive biosensing. With the ability to monitor
critical biomarkers, such as the hormone Vitamin D or Iron, we will inform users of potential health issues before symptoms manifest. Furthermore, our tests and paired App offers a new dimension in digital therapeutics, providing personalized health advice and management guidance more efficient ways than currently possible.

Faculty Supervisor:

Michael Serpe

Student:

Partner:

ChromaCare Labs Inc.

Discipline:

Life Sciences

Sector:

Health and Related Sciences & Technology; Retail trade

University:

University of Alberta

Program: